Precigen, Inc. (NASDAQ:PGEN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Precigen, Inc. (NASDAQ:PGEN) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.50.

PGEN has been the subject of several analyst reports. Wall Street Zen upgraded Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday. Citizens Jmp increased their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. HC Wainwright boosted their price objective on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a report on Wednesday.

Insider Activity

In other news, insider Donald P. Lehr sold 29,131 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider directly owned 755,461 shares of the company’s stock, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Harry Jr. Thomasian sold 171,429 shares of Precigen stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the transaction, the chief financial officer owned 354,535 shares in the company, valued at $1,960,578.55. The trade was a 32.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 989,239 shares of company stock worth $5,472,960 in the last 90 days. Insiders own 41.40% of the company’s stock.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently modified their holdings of PGEN. State of Wyoming bought a new position in Precigen during the first quarter worth $27,000. NBC Securities Inc. bought a new stake in Precigen in the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Precigen in the 3rd quarter worth $39,000. Royal Bank of Canada increased its holdings in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Precigen during the third quarter valued at about $41,000. 33.51% of the stock is owned by institutional investors.

Precigen Price Performance

NASDAQ PGEN opened at $7.23 on Tuesday. Precigen has a fifty-two week low of $1.70 and a fifty-two week high of $7.26. The stock’s 50-day moving average is $5.23 and its two-hundred day moving average is $4.50. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 4.12. The firm has a market cap of $2.58 billion, a P/E ratio of -6.95 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The company had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company’s quarterly revenue was up 6322.7% compared to the same quarter last year. On average, analysts anticipate that Precigen will post 0.05 earnings per share for the current fiscal year.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.